Clinical trials: GERD With Erosive Esophagitis, open to volunteers
Gut-Brain Disorders, GERD Without Erosive Esophagitis
Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.
Gastroesophageal reflux disease (GERD) poses a challenging medical condition to manage, with up to 40% of patients showing refractory to standard medical intervention, which usually begins with a proton pump inhibitor (PPI).
- Trial name
- NCT06778824
- Testing
- Takepron, Zoloft 50Mg Tablet, Imipramine Pill
- Where
- Taiwan
- Volunteers
- 610 people
- Sponsor
- Hualien Tzu Chi General Hospital
Gut-Brain Disorders, GERD Without Erosive Esophagitis
Cognitive-behavioral Therapy for the Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.
Gastroesophageal reflux disease (GERD) is a challenging gastrointestinal disorder, and proton pump inhibitors (PPIs) are typically the first line of treatment.
- Trial name
- NCT06939465
- Testing
- Cognitive Behavioral Therapy (CBT)
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Hualien Tzu Chi General Hospital
Erosive Esophagitis
Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis
The goal of this clinical trial is to compare drug vonoprazan vs esomeprazole effectiveness to relieve early symptoms in Erosive Esophagitis Patients. It will also learn about the safety of both modalities.
- Trial name
- INVEST (NCT06720610)
- Testing
- Vonoprazan 20 mg, Esomeprazole
- Where
- 5 sites in Indonesia
- Volunteers
- 216 people
- Sponsor
- Universitas Indonesia
Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)
Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive Esophagitis
This study aims to evaluate the Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects with Healed Erosive Esophagitis
- Trial name
- NCT07732075
- Testing
- JP-1366 10 mg, Lansoprazole 15mg
- Volunteers
- 384 people
- Sponsor
- Onconic Therapeutics Inc.
Gastroesophageal Reflux Disease With Esophagitis
PPI Dosing Per CYP2C19 Genotype
This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication…
- Trial name
- NCT07843264
- Testing
- CYP2C19 based dosing Proton Pump Inhibitors, Conventional proton pump inhibitor dose
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Florida